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Aims: In this study we wanted to figure out if there was a correlation between OPRM1
N40D, TRPV1 I316M, TRPV1 I585V, NOS3 −786T>C and IL6 −174C>G polymorphisms
and the response to locally applied articaine-epinephrine anesthetic.
Methods: In this observational study, 114 oral cell samples of patients anesthetized with
articaine-epinephrine (54 from men 60 from women), were collected from dental centers in
Madrid (Spain). High molecular weight DNAwas obtained from oral mucosa cells. The analysis
of OPRM1 N40D (rs1799971), TRPV1 I316M (rs222747), TRPV1 I585V (rs8065080) and IL6
−174C>G polymorphism was performed through real-time PCR allelic discrimination using
TaqMan probes. Polymorphism NOS3 −786T> C (rs2070744) was analyzed using RFLP-PCR.
Results: The studied polymorphisms are involved neither in the response to the anesthetic,
nor in the intensity of perceived dental pain. However, in a subset of female patients we
found that TRPV1 I316M was associated with a delayed onset of anesthesia.
Conclusions: There is no association among these polymorphisms and the time elapsed
between the application of the anesthetic and the onset of its effect.
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Introduction
Pain can be defined as an unpleasant experience associated with actual or potential
tissue damage. It is classically divided into nociceptive pain, which appears as the
normal response to tissue damage and pathological pain. The latter, in turn, can be
divided into inflammatory, which is produced by the action of mediators of inflam-
mation substances that act as promoters of nociception; or neuropathic, which is the
result of direct damage to the central or peripheral nervous system.
Pain perception is not a simple matter and, since it is influenced by a variety of
environmental and genetic factors1, individual differences in sensitivity and pain
tolerance are large. The severity of pain is controlled by genetic variants affecting
the expression or function of nociceptive sensory system components.2–4 However,
the pain inheritance patterns are complex and phenotypes are the result of the
expression of multiple differently distributed genes.
Since pain origin is polygenic, the combination of the alleles of different genes
can lead to different genotypes with different degrees of vulnerability that deter-
mine individual differences in the efficiency and kinetics of analgesics.
The effect of pain relief drugs is modulated by different factors such as the clinical
course, severity and individual perception of pain, factors that alter the pharmacoki-
netic mechanisms controlling the local availability of analgesic molecules at their site
of action, factors involved in the interaction of analgesic molecules with their target
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structures influencing the intensity of pain, factors that mod-
ulate opioid dosage requirements by conferring a risk of drug
addiction and side effects,3 and variations in genes coding for
proteins involved in all stages of drug interaction with the
body.5
Dental surgery induces transient nociceptive pain, and
different genes have been involved either in its perception or
in its response to analgesic drugs. For example, opioid pep-
tides, which function as neuromodulators of pain, and their
receptors, among which is the μ-Opioid receptor (OPRM1),
whose polymorphism cause variability in receptor density and
function, may explain the variation of responses among
patients6 and has been related to nociception.7 Transient recep-
tor potential cation channel subfamily V member 1 (TRPV1),
also known as the capsaicin receptor, is involved in neuro-
pathic pain8 as well as nociception.9 Nitric oxide synthases
(NOS), which are enzymes that synthesize nitric oxide (NO)
one of the most abundant neurotransmitters in the regulatory
processes of nociceptive stimulus, are also involved in noci-
ception, neuropathic and inflammatory pain.10–14 Interleukin-6
(IL-6) is one of the pro-inflammatory cytokines that modulate
the presence of extracellular and intracellular mediators that
are activated during transduction, conduction and transmission
of painful stimuli and it has been involved in nociception.15,16
As far as we know these polymorphisms are not involved in
articaine metabolism, and there is compelling evidence indi-
cating that they play a major role in pain response. Therefore,
these alleles are good candidates that require further study. To
this end, we analyzed, for the first time, the possible associa-
tion of anesthesia effectiveness with the OPRM1 N40D poly-
morphism, whose amino acid change in the extracellular
domain modifies its affinity for endogenous and exogenous
ligands such as β-endorphin.17 Moreover, the OPRM1
rs11799971 (c.118A>G; p. N40D) allele G is associated with
lower gene expression and a decreased number of cell surface
receptors.18,19 The polymorphisms of the TRPV1 gene I315M
and I585V, whose amino acids changes apparently do not alter
the structure or function of the receptor20 (allele M) have been
associated with a higher response to capsaicin, while TRPV1
rs8065080 (c.1191A>G; p.I585V) allele G has been associated
with a higher tolerance to pain and a lower capsaicin
response.21 The IL6 −174C>G polymorphism changes protein
expression levels22 and the NOS3 −786T>C polymorphism,
which regulates the transcription rate of the NOS3 gene and
has the ability to change enzyme levels, has been associated
with less promoter activity and protein expresion.23,24
We believe that for clinical practice it is of utmost
importance to understand the mechanism behind pain
production in the patients and thus in the future be able to
predict and avoid or reduce the possible pain produced by
the oral interventions. With this aim in mind, we recruited
both male and female healthy patients for carrying out an
observational study. Thus, we think that the aforementioned
four genes are strong candidates to play a role in nocicep-
tion and pain, so that the aim of our study was to analyze
OPRM1 N40D, TRPV1 I316M, TRPV1 I585V, IL6
−174C>G and NOS3 −786T>C polymorphisms and their
possible relationship with the articaine-epinephrine oral
anesthesia’s delayed time of onset and with pain perception.
Patients and methods
Patients
This observational study was carried out once informed
signed consent had been obtained from the participants. In
total, 114 oral cell samples (54 from men 60 from women)
were collected from dental centers in Madrid (Spain) from
May to December 2009. The ages of the patients included
in the study ranged between 18 and 92, with an average
age of 47.99±15 and a median of 48. The patients were
apparently healthy, of both sexes and had good oral
hygiene. The exclusion criteria were as follows: patients
with an active systemic infection or any other severe
uncontrolled systemic disease, diabetics and those with
thyroid endocrinopathy or fibromyalgia, patients who had
received head and neck radiation therapy and/or che-
motherapy, lactating women, and individuals with cogni-
tive impairment. The patients who had undergone
orthognathic, oral or implant surgery less than 1 year
prior to the onset of the study or with trauma in the
orofacial territory and/or associated structures were
excluded from the study. This also included patients who
had received more than 3 years of treatment with oral
bisphosphonates or less than 3 years of concomitant treat-
ment with immunosuppressant. Exclusion criteria also
included patients who smoked, and in particular those
who consumed more than 10 cigarettes a day.
This study was approved by the ethics board of
University of Salamanca and the University Hospital of
Salamanca and was in accordance with the Helsinki
declaration.
Samples were collected by unilateral exfoliative cytol-
ogy using simple, dry (without medium) and sterile swabs.
Then, the amide oral infiltrative anesthetic articaine with
epinephrine, was applied in the corresponding oral region
under intervention (Table S1).
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Subsequently, subjects were operated on using differ-
ent oral surgery techniques for dental implants and extrac-
tion. A protocol to collect clinical and demographic data
was developed, and surgery was performed in the mandib-
ular and maxillary area, numbered according to the sex-
tants defined by the International Dental Federation (IDF).
Anesthesia
A carpule of Ultracain® with epinephrine 40/0.01 mg/ml
containing 4% articaine vasoconstrictor epinephrine
1:100.000 (Normon S.A.) was applied to different anato-
mical regions of the oral cavity. Articaine is less toxic
than other drugs belonging to the same family due to the
presence of an additional ester group that is rapidly
hydrolyzed by plasma esterases, and this type of anesthe-
sia was chosen because of the latency, potency and dura-
tion of its effect on soft tissues compared to others with
similar chemical structures.25 The presence of
a vasoconstrictor in the solution, usually 1:200.000 adre-
naline or 1:100.000 epinephrine, decreases the rate of
absorption, resulting in lower latency and increased dura-
tion of action, so that lower doses are required and local
hemostasis is promoted.26,27
Pain scales
We performed an objective and a subjective analysis of
pain post-anesthetic administration. In all of the patients
who underwent surgery, pain measurements were made by
a single examiner. Onset time of the anesthesia was deter-
mined objectively with a stesiometer (Table 1). Objective
Table 1 Allelic frequencies of each polymorphism in patients under
study
Polymorphism p(A) q(a) P (χ2)
OPRM1 N40D 0.85 0.15 0.998
TRPV1 I316M 0.32 0.68 0.082
TRPV1 I585V 0.38 0.62 0.832
IL6 −174C>G 0.67 0.33 0.929
NOS3 −786T>C 0.37 0.63 0.608
Table 2 Genotype association with anesthesia onset
Genotype Up to 45 Up to 50 Up to 65
0–45 46 onwards 0–50 51-onwards 0–65 61-onwards
OPRM1 A/A 20 (21.7) 55 (53.3) 24 (25.7) 51 (49.3) 55 (52.6) 20 (22.4)
OPRM1 A/G 12 (10.4) 24 (25.6) 14 (12.3) 22 (23.7) 22 (25.3) 14 (10.7)
OPRM1 G/G 1 (0.9) 2 (2.1) 1 (1.0) 2 (2.0) 3 (2.1) 0 (0.9)
Result χ2 test value: 0.554 (n-1)=2 p=0.758 χ2 test value: 0.514 (n-1)=2 p=0.773 χ2 test value: 3.046 (n-1)=2 p=0.318
TPRVC315 C/C 1 (2) 6 (5.0) 2 (2.4) 5 (4.6) 6 (4.9) 1 (2.1)
TPRVC315 C/G 20 (17.4) 40 (42.6) 23 (20.5) 37 (39.5) 44 (42.1) 16 (17.1)
TPRVC315 G/G 12 (13.6) 35 (33.4) 14 (16.1) 33 (30.9) 30 (33) 17 (14)
Result χ2 test value: 1.559 (n-1)=2 p=0.459 χ2 test value: 0.961 (n-1)=2 p=0.619 χ2 test value: 1.998 (n-1)=2 p=0.368
TPRVC585 C/C 5 (4.1) 9 (9.9) 6 (4.8) 8 (9.2) 10 (9.8) 4 (4.2)
TPRVC585 C/T 13 (15.) 42 (39.1) 17 (18.8) 38 (36.2) 40 (38.6) 15 (16.4)
TPRVC585 T/T 15 (13.0) 30 (32.0) 16 (15.4) 29 (29.6) 30 (31.6) 34 (34)
Result χ2 test value: 1.487 (n-1)=2 p=0.475 χ2 test value: 0.768 (n-1)=2 p=0.681 χ2 test value: 0.446 (n-1)=2 p=0.800
IL6 G/G 17 (16.4) 39 (39.8) 18 (19.2) 38 (36.8) 37 (39.3) 19 (16.7)
IL6 G/C 12 (14.2) 37 (34.8) 17 (16.8) 32 (32.2) 35 (35.4) 14 (14.6)
IL6 C/C 4 (2.6) 5 (6.4) 4 (3.1) 5 (5.9) 8 (6.3) 1 (2.7)
Result χ2 test value: 1.578 (n-1)=2 p=0.454 χ2 test value: 0.530 (n-1)=2 p=0.737 χ2 test value: 1.578 (n-1)=2 p=0.454
eNOS786 C/C 5 (6.4) 17 (15.6) 7 (7.5) 15 (14.5) 15 (15.4) 8 (6.6)
eNOS786 C/T 19 (13.6) 28 (33.4) 21 (16.1) 26 (30.9) 37 (33) 10 (14.0)
eNOS786 T/T 9 (13.6) 36 (32) 11 (15.4) 34 (29.6) 29 (31.6) 45 (45.0)
Result χ2 test value: 0.5176 (n-1)=2 p=0.075 χ2 test value: 4252 (n-1)=2 p=0.119 χ2 test value: 2.796 (n-1)=2 p=0.247
Note: Expected frequencies are inside brackets.
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pain (Algometry) was assessed using a pressure algometer
(Von Frey’s Esthesiometer).28,29 Esthesiometer measure
the exteroceptive sensory. Designed by Sidney
Weinstein30 in the decade of the fifties of the last century,
it is formed by a set of 20 nylon monofilaments of equal
length and different amplitude that provide a logarithmic
scale of the applied real force and a linear scale of per-
ceived intensity. To normalize the distribution of the
dependent variable, the designer of the esthesiometer
designated the logarithm for the numerical value of the
pressure force as Log10 F (mg). The numerical values
obtained in the range of 1.65 to 6.65 mm in diameter,
equal to 0.008 and 300 force of pressure expressed in
grams respectively. Subjective pain was carried out using
a visual analog scale (VAS) with a range of 0 to 10, where
0 was nothing, 1–3 few, 4–7 much, and 8–10 unbearable.
Huskisson EC originally referenced VAS in 1974.31 This
method, evaluates in one person the intensity of pain and
its evolution over time. As the pain analyzed is subjective,
it is not useful to compare the intensity of pain among
different people, since each individual has a different
perception of pain. It consists of a line of 10 cm that
represents the continuous spectrum of the painful experi-
ence; the left end means “no pain“ and the right ”the worst
pain imaginable.” In this scale the patient must indicate the
intensity of his painful sensation, which will be measured,
with a ruler, by the examiner from his left end to the point
indicated.
Thus, we also searched for a relationship between
polymorphisms and subjective pain at different times:
15 seconds and 45 seconds from the application of the
anesthetic. Subjects were grouped by pain ranges based on
VAS values below or over 2. In the last case, those sub-
jects in whom the anesthetic had taken effect were
removed from the study. Thus, the frequency of genotypes
of different polymorphisms in each of the other groups
was studied to see whether there were any polymorphisms
involved in the individual’s susceptibility to pain.
DNA extraction
High molecular weight DNA was obtained from oral
mucosa cells. Isolation and cell lysis were carried out
Table 3 Genotype association in men with anesthesia onset in men
Genotype Up to 40 Up to 50 Up to 65
0–45 46 onwards 0–50 51-onwards 0–65 61-onwards
OPRM1 A/A 5 (7.3) 31 (28.7) 8 (10.7) 28 (25.3) 23 (24) 13 (12)
OPRM1 A/G 5 (3.1) 10 (11.9) 7 (4.4) 8 (10.6) 10 (10) 5 (5)
OPRM1 G/G 1 (0.6) 2 (2.4) 1 (0.9) 2 (2.1) 3 (2) 0 (1)
Result χ2 test value: 2.797 (n-1)=2 p=0.247 χ2 test value: 3.055 (n-1)=2 p=0.217 χ2 test value: 1.625 (n-1)=2 p=0.444
TPRVC315 C/C 0 (0.6) 3 (2.4) 1 (0.9) 2 (2.1) 3 (2.0) 0 (1.0)
TPRVC315 C/G 6 (5.3) 20 (20.7) 8 (7.7) 18 (18.3) 15 (17.3) 11 (8.7)
TPRVC315 G/G 5 (5.1) 20 (19.9) 7 (7.4) 18 (17.6) 18 (16.7) 7 (8.3)
Result χ2 test value: 0.887 (n-1)=2 p=0.642 χ2 test value: 0.068 (n-1)=2 p=0.967 χ2 test value: 2.762 (n-1)=2 p=0.251
TPRVC585 C/C 1 (1.4) 6 (5.6) 2 (2.1) 5 (4.9) 4 (4.7) 3 (2.3)
TPRVC585 C/T 5 (5.7) 23 (22.3) 8 (8.3) 20 (19.7) 20 (18.7) 8 (9.3)
TPRVC585 T/T 5 (3.9) 14 (15.1) 6 (5.6) 13 (13.4) 12 (12.7) 7 (6.3)
Result χ2 test value: 0.683 (n-1)=2 p=0.711 χ2 test value: 0.053 (n-1)=2 p=0.974 χ2 test value: 0.677 (n-1)=2 p=0.713
IL6 G/G 5 (4.9) 19 (19.1) 6 (7.1) 18 (16.9) 13 (16) 11 (8)
IL6 G/C 3 (5.1) 22 (19.9) 7 (7.4) 18 (17.6) 19 (16.7) 6 (8.3)
IL6 C/C 3 (1.0) 2 (4.0) 3 (1.5) 2 (3.5) 4(3.3) 1 (1.7)
Result χ2 test value: 5.942 (n-1)=2 p=0.052 χ2 test value: 2.490 (n-1)=2 p=0.288 χ2 test value: (n-1)=2 p=0.216
eNOS786 C/C 3 (3.3) 13 (12.7) 5 (4.7) 11 (11.3) 9 (19.7) 7 (5.3)
eNOS786 C/T 5 (3.7) 13 (14.3) 6 (5.3) 12 (12.7) 15 (12) 3 (6)
eNOS786 T/T 3 (4.1) 17 (15.9) 5 (5.9) 15 (14.1) 12 (13.3) 8 (6.7)
Result χ2 test value: 0.990 (n-1)=2 p=0.609 χ2 test value: 0.344 (n-1)=2 p=0.882 χ2 test value: 3.431 (n-1)=2 p=0.183
Note: Expected are inside brackets.
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using buffer Fornace (0.25 M Sucrose, 50 mM Tris-HCl
pH: 7.5, 25 mM KCl, 5 mM MgCl2), chelating agent
EDTA (0.5M, pH=8), proteinase K (Boehringer
Mannheim, 20 mg/mL) and SDS (1%). In total 118
patients were recruited, but for 4 of them we were
unable to genotype the four genes owing to technical
problems.
The mixture was incubated at 55 °C for 16 hrs and the
process of DNA extraction and purification was performed
using phenol-chloroform, isoamyl-alcohol, absolute ethanol
and 70% ethanol. The DNAwas resuspended in sterile ddH2
O and frozen at −80 ºC until used. Some of the extracted
samples showed very low DNA concentrations, requiring
genomic DNA amplification using Illustra™ V2 DNA
Amplification Kit GenomiPhi (GE Healthcare, Amersham
Biosciences).
Real-time PCR allelic discrimination
The analysis of OPRM1N40D (rs1799971), TRPV1 I316M
(rs222747) and TRPV1 I585V (rs8065080) polymorphisms
was performed through real-time PCR allelic discrimina-
tion using TaqMan probes. The final volume of the reaction
consisted of 10μl, and commercial mixtures of primers and
TaqMan MGB® probes (C_89500741, C_1093688 and
C_11679656) (Applied Biosystems), alongside the mixture
TaqMan® Universal PCR Master Mix No AmpErase®
UNG (Applied Biosystems) containing the DNA polymer-
ase, were used. The amplification program for both poly-
morphisms involved 40 one-minute cycles at an annealing
temperature of 60 ºC. The PCR reactions were carried out
using the TaqMan© universal PCR Master Mix in a Step-
One Plus Real-time PCR system, following the manufac-
turer’s instructions. To assess reproducibility, 5% of the
samples were randomly selected and re-genotyped, and all
genotypes matched those originally obtained. The follow-
ing probes were obtained from Thermofisher®:rs11799971:
C__3204138_10, rs222747: C__1093688_20, rs8065080:
C__11679656_10, rs2070744: C_15903863_10.
The allelic discrimination of IL6 −174C>G
(rs1800795) polymorphism was performed by real time
Table 4 Genotype association with anesthesia onset in female
Genotype Up to 45 Up to 50 Up to 65
0–45 46 onwards 0–50 51-onwards 0–65 61-onwards
OPRM1 A/A 15 (14.3) 24 (24.7) 16 (15.1) 23 (24.1) 16 (15) 23(24.1)
OPRM1 A/G 7 (7.7) 14 (13.3) 7 (8.1) 14 (13) 7 (8.1) 14 (13)
OPRM1 G/G - - - - - -
Result χ2 test value: 0.155 (n-1)=2 p=0.458 χ2 test value: 0.342 (n-1)=2 p=0.382 χ2 test value: 0.431 (n-1)=2 p=0.067
TPRVC315 C/C 1 (1.5) 3 (2.5) 1 (1.5) 3 (2.5) 3 (2.9) 1 (1.1)
TPRVC315 C/G 14 (12.5) 20 (21.5) 15 (13) 19 (21) 29 (24.9) 5 (9.1)
TPRVC315 G/G 7 (8.1) 15 813.9) 7 (8.4) 15 (13.6) 12 (16.1) 10 (5.9)
Result χ2 test value: 0.755 (n-1)=2 p=0.688 χ2 test value: 1.177 (n-1)=2 p=0.555 χ2 test value: 6.464 (n-1)=2 p=0.039
TPRVC585 C/C 4 (2.6) 3 (4.4) 4 (2.7) 3 (4.3) 6 (5.1) 1 (1.9)
TPRVC585 C/T 8 (9.9) 19 (17.1) 9 (10.4) 18 (16.7) 20 (19.8) 7 (7.2)
TPRVC585 T/T 10 (9.5) 16 (16.5) 10 (10.0) 16 (16.0) 18 (19.1) 8 (6.9)
Result χ2 test value: 1.876 (n-1)=2 p=0.391 χ2 test value: 1.333 (n-1)=2 p=0.513 χ2 test value: 0.780 (n-1)=2 p=0.677
IL6 G/G 12 (11.7) 20 (20.3) 12 (12.3) 20 (19.7) 24 (23.5) 8 (8.5)
IL6 G/C 9 (8.8) 15 (15.2) 10 (9.2) 14 (14.8) 16 (17.6) 8 (6.4)
IL6 C/C 1 (1.5) 3 (2.5) 1 (1.5) 3 (2.5) 4 (2.9) 0 (1.1)
Result χ2 test value: 0.251 (n-1)=2; p=0.889 χ2 test value: 0.423 (n-1)=2; p=0.809 χ2 test value: (n-1)=2 p=0.360
eNOS786 C/C 2 (2.2) 4 (3.8) 2 (2.3) 4 (3.7) 5 (4.4) 1 (1.6)
eNOS786 C/T 14 (10.6) 15 (18.4) 15 (11.1) 14 (17.9) 22 (21.3) 7 (7.7)
eNOS786 T/T 6 (9.2) 19 (15.8) 6 (9.6) 19 (15.4) 17 (18.3) 8 (6.7)
Result χ2 test value: 3.439 (n-1)=2 p=0.171 χ2 test value: 4.436 (n-1)=2 p=0.109 χ2 test value: 0.765 (n-1)=2 p=0.682
Note: Expected frequencies are inside brackets.
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PCR using designed probes and primers. The forward
primer’s sequence was 5´-TGACGACCTAA
GCTGCACTTTTC-3´ and that of the reverse primer was
5´-GGGCTGATTGGAAACCTTATTAAGA-3´. Probes
were VIC: TCTTGCGATGCTAAA and FAM:
TCTTGCCATGCTAAA, and the annealing temperature
was 57ºC for 40 one-minute cycles. Genotyping was per-
formed at the Biomedical Research Institute of Salamanca
(IBSAL) in small batches.
Allelic discrimination by RFLP-PCR
NOS3 −786T>C (rs2070744) polymorphism was analyzed
using RFLP-PCR. PCR amplification reactions were per-
formed in a volume of 25 µl and consisted of 0.6 U Taq
DNA polymerase, 400 µM of each dNTP, 3.0mM MgCl2,
5 pmol of each forward primer 5‘-TCTACAGTCCCCCT
TGCCGT-3‘ and reverse primer 5’-CTGACCGTGCA
AGTCACAGA-3’. The amplification program consisted
of 35 cycles involving denaturation at 95 °C for 30 sec-
onds, annealing of primers at 60 °C for 30 seconds and
primer extension at 72 °C for 30 seconds. All amplification
reactions were carried out in an automatic thermocycler
Abi verity 96 well (Applied Biosystem). The correct
amplification of 180 bp fragments was
confirmed by horizontal electrophoresis using 2% agar-
ose gel. The PCR product was digested with 1U of the
restriction enzyme PdiI (Fermentas), which recognizes the
cleavage site in the sequence generated by the nucleotide
change. Digestion was carried out for 8–10 hrs at 37 ºC.
DNA fragments were resolved by horizontal electrophor-
esis using 3% agarose gel, generating three different pat-
terns for the three possible genotypes: (C/C) fragments of
87 bp and 93 bp; (T/T) one fragment of 180 bp; and (C/T)
three fragments of 180 bp, 87 bp and 93 bp.
Statistical analysis
Sample size was estimated using the software Gpower
3.1.9.2 for correlation analysis, assuming an alpha and
beta error of 0.5 and 0.95, respectively, with a side effect
of 0.32. In addition, the minimum number of 100 samples
was needed for carrying out the study. The statistical
contingency test (χ2) analysis was performed using SPSS
Table 5 Genotype association with pain at 15 and 45 seconds from anesthesia administration
Genotype EVA 15´´ EVA 45´´
VAS 0–1 VAS 2 or more VAS<1 1 or 2
OPRM1 A/A 61 (59.9) 15 (14.9) 32 (18) 18 (18.4)
OPRM1 A/G 28 (28.7) 9 (7.3) 14 (15.4) 10 (8.8)
OPRM1 G/G 3 (2.4) 0 (0.6) 2 (1.3) 0 (0.7)
Result χ2 test value: 1.385 (n-1)=2; p=0.500 χ2 test value: 1.422 (n-1)=2; p=0.491
TPRVC315 C/C 6 (5.6) 1 (1.4) 4 (3.2) 1 (1.8)
TPRVC315 C/G 49 (47.9) 11 (12.1) 24 (24.0) 14 (14.0)
TPRVC315 G/G 36 (37.5) 11 (9.5) 20 (20.8) 13 (12.2)
Result χ2 test value: 0.581 (n-1)=2; p=0.781 χ2 test value: 0.702 (n-1)=2; p=0.704
TPRVC585 C/C 11 (11.2) 3 (2.8) 5 (5.1) 3 (2.9)
TPRVC585 C/T 44 (43.9) 11 (11.1) 25 (24.6) 14 (14.4)
TPRVC585 T/T 36 (35.9) 9 (9.1) 18 (18.3) 11 (10.7)
χ2 test value: 0.016 (n-1)=2; p=0.992 χ2 test value: 0.031 (n-1)=2; p=0.985
IL6 G/G 45 (44.7) 11 (11.3) 25 (23.4) 12 (13.6)
IL6 G/C 38 (39.1) 11 (9.9) 19 (21.5) 15 (12.5)
IL6 C/C 8 (7.2) 1 (1.8) 4 (3.2) 1 (1.8)
Result χ2 test value: 0.626 (n-1)=2; p=0.731 χ2 test value: 1.692 (n-1)=2; p=0.429
eNOS786 C/C 16 (17.6) 6 (4.4) 8 (9.5) 7 (5.5)
eNOS786 C/T 40 (37.5) 7 (9.5) 17 (16.4) 9 (9.6)
eNOS786 T/T 35 (35.9) 10 (9.1) 23 (22.1) 12 (12.9)
Result χ2 test value: 1.169 (n-1)=2; p=0.445 χ2 test value: 0.776 (n-1)=2; p=0.678
Note: Expected frequencies are inside brackets.
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v.18 software for Windows. Differences in genotypic and
allelic distribution among different groups and Hardy-
Weinberg equilibrium were determined using the chi-
square test (χ2). P-values (p) less than 0.05 were consid-
ered significant.
Results
We initially set out to test whether the groups included in
this study were in accordance with the Hardy-Weinberg
equilibrium, which involved conducting a χ2 test. Table 1
shows the allelic frequencies of our population and the
p-value associated with the χ2 test. All probabilities were
above of 0.05 therefore our groups were in accordance
with this law.
Initial algometry in all patients, measured with Von
Frey esthesiometer, was 6.65 (mm). We established three
periods of anesthesia corresponding to three kinds of
patients with respect to their pain response: fast responders
(up to 45 seconds), the medium responders (up to 50 sec-
onds) and the low responders (up to 65 seconds).
Analyzing all the patients, none of the five polymorphisms
showed significant differences when comparing the fre-
quency of genotypes between the different groups and
the onset of anesthesia after administration of Ultracain®
(Table 2). Thus, we concluded that there was no associa-
tion between polymorphism and the onset anesthesia time.
Additionally it was tested whether gender had an influence
on the onset of anesthesia in combination with polymorph-
ism presence. Results are shown in Tables 3 and 4 for men
and female respectively. It was found that in women there
was a significant association between the genotype
TPRVC315 and longer response times to anesthesia. In
particular, there were more patients with anesthesia time
greater than 65 seconds than was expected (10 vs 5.9).
We are aware that pain is a subjective feeling; there-
fore for the purpose of normalization, two time points
were established for comparing the feeling of pain in all
groups (15 and 45 seconds). In this comparison we also
did not find any relationship between the polymorphisms
being analyzed and the feeling of pain, assessed subjec-
tively using VAS scales as shown in Table 5.
Furthermore, no associations were found among the
Table 6 Genotype association with pain at 15 and 45 seconds from anesthesia administration in females
Genotype EVA 15´´ EVA 45´´
VAS 0–1 VAS 2 or more VAS<1 1 or 2
OPRM1 A/A 61 (59.9) 15 (14.9) 32 (18) 18 (18.4)
OPRM1 A/G 28 (28.7) 9 (7.3) 14 (15.4) 10 (8.8)
OPRM1 G/G 3 (2.4) 0 (0.6) 2 (1.3) 0 (0.7)
Result χ2 test value: 1.385 (n-1)=2; p=0.500 χ2 test value: 1.422 (n-1)=2; p=0.491
TPRVC315 C/C 6 (5.6) 1 (1.4) 4 (3.2) 1 (1.8)
TPRVC315 C/G 49 (47.9) 11 (12.1) 24 (24.0) 14 (14.0)
TPRVC315 G/G 36 (37.5) 11 (9.5) 20 (20.8) 13 (12.2)
Result χ2 test value: 0.581 (n-1)=2; p=0.781 χ2 test value: 0.702 (n-1)=2; p=0.704
TPRVC585 C/C 11 (11.2) 3 (2.8) 5 (5.1) 3 (2.9)
TPRVC585 C/T 44 (43.9) 11 (11.1) 25 (24.6) 14 (14.4)
TPRVC585 T/T 36 (35.9) 9 (9.1) 18 (18.3) 11 (10.7)
χ2 test value: 0.016 (n-1)=2; p=0.992 χ2 test value: 0.031 (n-1)=2; p=0.985
IL6 G/G 45 (44.7) 11 (11.3) 25 (23.4) 12 (13.6)
IL6 G/C 38 (39.1) 11 (9.9) 19 (21.5) 15 (12.5)
IL6 C/C 8 (7.2) 1 (1.8) 4 (3.2) 1 (1.8)
Result χ2 test value: 0.626 (n-1)=2; p=0.731 χ2 test value: 1.692 (n-1)=2; p=0.429
eNOS786 C/C 16 (17.6) 6 (4.4) 8 (9.5) 7 (5.5)
eNOS786 C/T 40 (37.5) 7 (9.5) 17 (16.4) 9 (9.6)
eNOS786 T/T 35 (35.9) 10 (9.1) 23 (22.1) 12 (12.9)
Result χ2 test value: 1.169 (n-1)=2; p=0.445 χ2 test value: 0.776 (n-1)=2; p=0.678
Note: Expected frequencies are inside brackets.
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feeling of pain, the sex of the patient and the various
polymorphisms (Tables 6 and 7).
Discussion
Pain is a complex process that involves numerous factors. It
is known that age, gender, or psychological and ethnic factors
may modify pain perception,32–34 and there are several stu-
dies on the interaction between an individual’s genetic basis
and their response to painful stimuli.1,3,35
Articaine is a short-acting local anesthetic belonging to the
amide group. Epinephrine acts as a vasoconstrictor to promote
local hemostasis and reduce systemic absorption of local anes-
thetic. Therefore, their combination induces anesthesia within
1 to 6 mins and its effect stands for several hours.26 In our
study, patients showed different times of onset of action of
anesthesia and different pain sensation levels. This variability
is due to individual differences, and its origin is yet unclear,
since there are very few genetic studies that provide data on the
onset and duration of anesthesia. Thus, we analyzed OPRM1
N40D, TRPV1 I316M, TRPV1 I585V, IL6 −174C>G and
NOS3 −786T>C polymorphisms in subjects treated with
local anesthetic articaine with epinephrine before dental
surgery.
According to our findings, there is no association
between these polymorphisms and the time elapsed
between the application of the anesthetic and the onset of
its effect. There are no differences between patients before
and after 45, 50, and 65 seconds. Likewise, subjective pain
intensity, measured by VAS, bears no relationship with
them, because no differences were found in the frequency
of appearance of the genotypes. However, it is true that in
women an association was found between TPRVC315 G/G
and a delayed time of anesthesia. At present, the reason for
why this occurs is unknown, but we believe that new
studies with larger numbers of patients may corroborate
this finding.
As far as we know, this is the first attempt to find
a relationship between local oral anesthesia and genetic varia-
bility. Regarding polymorphism related to OPRM1 and sensi-
tivity to analgesic, we have only found a previous study by
Table 7 Genotype association with pain at 15 and 45 seconds from anesthesia administration in females
Genotype EVA 15´´ EVA 45´´
VAS 0–1 VAS 2 or more VAS<1 1 or 2
OPRM1 A/A 34 (32.5) 5 (6.5) 18 (17.1) 6 (6.9)
OPRM1 A/G 16 (17.5) 5 (3.5) 9 (9.9) 5 (4.1)
OPRM1 G/G - -
Result χ2 test value: 1.187 (n-1)=2; p=0.298 χ2 test value: 0494 (n-1)=2; p=0.712
TPRVC315 C/C 3 (3.3) 1 (0.7) 2 (2.1) 1 (0.9)
TPRVC315 C/G 31 (28.3) 3 (5.7) 16 (14.6) 4 (5.8)
TPRVC315 G/G 16 (18.3) 6 (3.7) 9 (10.7) 6 (4.3)
Result χ2 test value: 3.488 (n-1)=2; p=0.175 χ2 test value: 1.697 (n-1)=2; p=0.428
TPRVC585 C/C 6 (5.8) 1 (1.2) 2 (2.1) 1 (0.9)
TPRVC585 C/T 22 (22.5) 5 (4.5) 13 (13.5) 6 (5.5)
TPRVC585 T/T 22 (21.7) 4 (4.3) 12 (11.4) 4 (4.6)
χ2 test value: 0.126 (n-1)=2; p=0.919 χ2 test value: 0.213 (n-1)=2; p=0.899
IL6 G/G 28 (26.7) 4 (5.3) 16 (14.2) 4 (5.8)
IL6 G/C 18 (20.0) 6 (4.0) 8 (10.7) 7 (4.3)
IL6 C/C 4 (3.3) 0 (0.7) 3 (2.1) 0 (0.9)
Result χ2 test value: 2.400 (n-1)=2; p=0.301 χ2 test value: 4.290 (n-1)=2; p=0.117
eNOS786 C/C 5 (5.0) 1 (1.0) 3 (2.8) 1 (1.2)
eNOS786 C/T 24 (24.2) 5 (4.8) 9 (10.7) 6 (4.3)
eNOS786 T/T 21 (20.8) 4 (4.2) 15 (13.5) 4 (5.5)
Result χ2 test value: 0.015 (n-1)=2; p=0.993 χ2 test value: 1.497 (n-1)=2; p=0.473
Note: Expected frequencies are inside brackets.
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Fukuda et al (2010)36 in which the authors reported that SNP
A118G, which was related to response to morphine doses in
cancer patients, was responsible for differences in sensitive to
fentanyl. In the case of TRPV1 (rs8065080) our results agree
with a previous study were authors failed in finding any asso-
ciation between this polymorphism and chronic postoperative
pain in patients of thoracic cosmetic surgery.37
On the other hand, we are aware that the limitation of
this study is the number of patients and perhaps in the
future a study designed with more patients might find any
association between the studied polymorphisms and the
anesthesia onset. We also are aware that comparing the
pain feeling is difficult between patients given the differ-
ences places of anesthesia application and probably the
different diffusion of the drug in each patient. For these
reasons, we tried to sort the patients out with an arbitrary
VAS of 2 in 15 and 45 seconds. However, we also failed to
find any correlation with this aggrupation.
Thus, we concluded that there was not association among
the polymorphism under study and anesthesia onset. However,
we also believe that it cannot be ruled out that variations in
other genes may be involved in individual susceptibility to
local anesthesia with articaine-epinephrine.
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Supplementary material
Table S1 Anesthesia region, onset time, and VAS evaluation for each patient
#Patient Anesthesia region VAS
15´´
VAS
30´´
VAS
45´´
VAS
60´´
VAS
75´´
VAS
90´´
VAS
105´´
VAS
120´´
Onset time (seconds)
1 36–37 1 1 0.5 0 60
2 36 1 0.5 0 45
3 36 2 2 1 1 0.5 0 90
4 26 2 2 1 1 0.5 0 90
5 11–12 1 0.5 0 45
6 22 1 1 0.5 0 0 75
7 26 2 2 1 1 0.5 0 90
8 23 1 1 0.5 0 60
9 47 2 2 1 1 0.5 0 90
10 46 2 2 1 1 0.5 0 90
11 13 2 2 2 1 1 0 0 0 120
12 28 2 2 1 1 0.5 0 90
13 36 1 1 0.5 0 60
14 36 2 2 2 2 1 1 1 1 180
15 25 0 0 30
16 21–23 2 2 1 1 0.5 0 90
17 35 2 2 2 1 1 0 0 0 110
18 36 1 1 0.5 0 60
19 11–21 0 0 30
20 32–42 1 1 0.5 0 60
21 16 1 0.5 0 45
22 26 0 0 30
23 35–36 1 1 0.5 0 60
24 38 1 0.5 0 45
25 15 1 1 0.5 0 60
26 23 1 1 0.5 0 60
27 46 1 1 0.5 0 0 70
28 37 2 2 2 1 1 0 0 0 110
29 12 2 2 2 1 1 0 0 0 105
30 35 1 1 0.5 0 60
31 42 2 2 2 1 1 0 0 0 120
32 33–43 1 1 0.5 0 60
33 36 1 0.5 0 48
34 17 2 2 1 1 0.5 0 90
35 26 2 2 2 1 1 0 0 0 105
36 25 1 1 0.5 0 60
37 36 1 1 0.5 0 60
(Continued)
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Table S1 (Continued).
#Patient Anesthesia region VAS
15´´
VAS
30´´
VAS
45´´
VAS
60´´
VAS
75´´
VAS
90´´
VAS
105´´
VAS
120´´
Onset time (seconds)
38 38 1 0.5 0 45
39 33–43 2 2 1 1 0.5 0 90
40 22 1 1 0.5 0 60
41 25 2 2 2 1 1 0 0 0 120
42 13 1 1 0 0 59
43 36 2 2 1 1 0.5 0 90
44 15 1 1 0.5 0 0 75
45 45–46 1 1 0.5 0 0 65
46 14 1 1 0.5 0 0 70
47 46 1 0.5 0 45
48 46–47 1 0.5 0 45
49 46 2 2 2 1 1 0 0 0 120
50 45 1 0.5 0 50
51 37 1 1 0.5 0 60
52 26 1 0.5 0 45
53 25 1 1 0.5 0 60
54 31–41 1 0.5 0 45
55 46 1 1 0.5 0 60
56 46 1 1 0.5 0 60
57 16 1 1 0.5 0 60
58 26 3 2 2 2 2 2 2 1 240
59 23 1 1 0.5 0 0 75
60 46 1 1 0.5 0 60
61 21 1 1 0.5 0 60
62 25 1 1 0.5 0 60
63 14–16 1 0.5 0 45
64 16 1 1 0.5 0 60
65 47 0 0 40
66 47–48 1 0.5 0 45
67 46 0 0 30
68 14 1 1 0.5 0 60
69 35 1 0.5 0 45
70 38 1 1 0.5 0 60
71 38 2 2 1 1 0.5 0 90
72 12 1 0.5 0 45
73 16 1 1 0.5 0 60
74 46 1 1 0.5 0 60
75 13 1 1 0.5 0 0 70
76 15 0 0 30
(Continued)
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Table S1 (Continued).
#Patient Anesthesia region VAS
15´´
VAS
30´´
VAS
45´´
VAS
60´´
VAS
75´´
VAS
90´´
VAS
105´´
VAS
120´´
Onset time (seconds)
77 13–23 1 0.5 0 45
78 33–43 1 1 0.5 0 0 75
79 23 1 1 0.5 0 60
80 24–26 1 0.5 0 45
81 46 1 0.5 0 45
82 11–22 2 2 2 1 1 0 0 0 120
83 46 1 1 0.5 0 60
84 35–36 1 0.5 0 45
85 23 0 0 30
86 46 1 1 0.5 0 60
87 46 0 0 30
88 46 1 0.5 0 45
89 21 0 0 35
90 11–13 1 1 0.5 0 60
91 36 1 0.5 0 45
92 16 1 1 0 0 0 65
93 16 1 1 0.5 0 0 70
94 46 1 1 0.5 0 60
95 46 2 2 2 1 1 0 0 0 120
96 47 1 1 0.5 0 0 70
97 37 2 2 2 1 1 0 0 0 120
98 46 1 1 0.5 0 60
99 32–42 1 1 0.5 0 60
100 26 1 0.5 0 0 55
101 33–43 2 1 1 0.5 0 0 80
102 37 1 0.5 0 50
103 48 1 1 0.5 0 60
104 36 1 1 0.5 0 60
105 36 1 1 0,5 0 55
106 45 1 1 0.5 0 60
107 27 0 0 35
108 38 1 0.5 0.5 55
109 47 2 2 1 1 0.5 0 90
110 47 1 1 0.5 0 60
111 13 1 1 0.5 0 55
112 25–26 0 0.5 0 45
113 15 1 1 0 0 50
114 33 1 1 0 0 50
Notes: VAS Scale key: 0 was nothing, 1–3 few, 4–7 much, and 8–10 unbearable.
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